Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 51 of 114, showing 5 Applications out of 567 total, starting on record 251, ending on 255

# Protocol No Study Title Investigator(s) & Site(s)

251.

ECCT/16/02/03   EFFECT OF LOW-DOSE KETAMINE VERSUS FENTANYL ON ATTENUATING THE HAEMODYNAMIC RESPONSE TO LARYNGOSCOPY AND ENDOTRACHEAL INTUBATION IN PATIENTS UNDERGOING GENERAL ANAESTHESIA
    EFFECT OF LOW-DOSE KETAMINE VERSUS FENTANYL ON ATTENUATING THE HAEMODYNAMIC RESPONSE TO LARYNGOSCOPY AND ENDOTRACHEAL INTUBATION IN PATIENTS UNDERGOING GENERAL ANAESTHESIA AT THE AGA KHAN UNIVERSITY HOSPITAL, NAIROBI   
Principal Investigator(s)
1. Angela Ongewe
Site(s) in Kenya
Aga Khan University Hospital, Nairobi
 
View

252.

ECCT/24/02/05   Doxo-study
    Pharmacokinetic profiles for Doxorubicin among children with childhood cancer in Kenya.           
Principal Investigator(s)
1. Festus MUIGAI Njunguna
Site(s) in Kenya
MOI UNIVERSITY SCHOOL OF MEDICINE
 
View

253.

ECCT/14/03/01  
    Comparison of School and Community-based Mass Drug    Administration Delivery Strategies for Control of Schistosoma mansoni Infections in Western Kenyan in Areas with > 25% Prevalence       
Principal Investigator(s)
1. Mwinzi Ngina Mwinzi
Site(s) in Kenya
Nyanza region
 
View

254.

ECCT/19/04/01   A study to determine if a new shigella vaccine (Shigella4V) is safe, induces immunity and the best dose among Kenyan infants.
    Safety and immunogenicity of a Shigella-tetravalent bioconjugate vaccine: A phase 1/2 randomized controlled and age descending study including dose finding in 9-month-old infants   
Principal Investigator(s)
1. Mainga Hamaluba
2. Kosgei Josphat
Site(s) in Kenya
1. KEMRI-United States Army Medical Research Unit-Kenya, Kericho (Kericho county)
2. KEMRI Wellcome Trust Research Program-CGMR-C (Kilifi county)
 
View

255.

ECCT/19/04/02   NADIA \"Nucleosides And Darunavir/Dolutegravir In Africa\"
    A randomised controlled trial of darunavir versus dolutegravir and tenofovir versus zidovudine in second-line antiretroviral therapy regimens for the public health approach in sub-Saharan Africa   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
Moi University Clinical Research Centre
 
View